Analysts are on the Bearish side about Versartis, Inc. (NASDAQ:VSAR) this week.

January 19, 2018 - By Adrian Mccoy

 Analysts are on the Bearish side about Versartis, Inc. (NASDAQ:VSAR) this week.
Investors sentiment decreased to 1.29 in 2017 Q3. Its down 0.10, from 1.39 in 2017Q2. It turned negative, as 25 investors sold Versartis, Inc. shares while 24 reduced holdings. 35 funds opened positions while 28 raised stakes. 16.86 million shares or 34.93% less from 25.90 million shares in 2017Q2 were reported.
Art Advisors Limited Liability Corporation holds 28,520 shares. Alpinvest Prtn Bv holds 33,076 shares. Baker Bros Advsrs L P stated it has 0.03% of its portfolio in Versartis, Inc. (NASDAQ:VSAR). Mufg Americas Corporation has 0% invested in Versartis, Inc. (NASDAQ:VSAR). Vanguard Grp Inc has 1.23M shares for 0% of their portfolio. Two Sigma reported 28,361 shares. Cubist Systematic Strategies Ltd Liability invested in 850 shares or 0% of the stock. Ancora Advisors Ltd Liability Corporation invested in 0.01% or 50,000 shares. Bogle Invest Mgmt L P De reported 72,320 shares. Pura Vida Limited Liability Corp reported 100 shares. Rhumbline Advisers invested in 36,268 shares or 0% of the stock. Legal & General Gp Public Lc, United Kingdom-based fund reported 8,100 shares. Goldman Sachs Grp Inc has invested 0% in Versartis, Inc. (NASDAQ:VSAR). First Quadrant Ltd Partnership Ca reported 120,500 shares. Swiss Bancorp holds 0% of its portfolio in Versartis, Inc. (NASDAQ:VSAR) for 40,200 shares.

Since September 21, 2017, it had 0 buys, and 5 sales for $7.02 million activity. The insider Hislop Colin sold $1,701. Brumm Joshua T also sold $3,381 worth of Versartis, Inc. (NASDAQ:VSAR) shares. 776 shares were sold by Ward Shane, worth $1,979 on Thursday, October 19. The insider PERCEPTIVE ADVISORS LLC sold 2.13 million shares worth $7.01M.

Versartis, Inc. (NASDAQ:VSAR) Ratings Coverage

Among 12 analysts covering Versartis Inc (NASDAQ:VSAR), 6 have Buy rating, 1 Sell and 5 Hold. Therefore 50% are positive. Versartis Inc had 26 analyst reports since August 13, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Versartis, Inc. (NASDAQ:VSAR) on Friday, September 22 with “Overweight” rating. The stock of Versartis, Inc. (NASDAQ:VSAR) has “Equal-Weight” rating given on Friday, September 22 by Morgan Stanley. The firm has “Overweight” rating given on Tuesday, October 4 by Piper Jaffray. The rating was downgraded by Cowen & Co on Friday, September 22 to “Market Perform”. Credit Suisse downgraded Versartis, Inc. (NASDAQ:VSAR) on Thursday, December 17 to “Underperform” rating. The firm has “Buy” rating given on Friday, September 22 by Canaccord Genuity. Northland Capital initiated the stock with “Outperform” rating in Thursday, April 7 report. The stock of Versartis, Inc. (NASDAQ:VSAR) has “Buy” rating given on Tuesday, June 27 by Piper Jaffray. The rating was downgraded by Barclays Capital to “Underweight” on Friday, September 22. The stock of Versartis, Inc. (NASDAQ:VSAR) has “Hold” rating given on Friday, September 22 by SunTrust. Below is a list of Versartis, Inc. (NASDAQ:VSAR) latest ratings and price target changes.

25/09/2017 Broker: Citigroup Rating: Hold New Target: $3.0 Downgrade
22/09/2017 Broker: Citigroup Rating: Hold New Target: $3.0 Downgrade
22/09/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $28 New Target: $9 Maintain
22/09/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $17 New Target: $3 Maintain
22/09/2017 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Downgrade
22/09/2017 Broker: Cantor Fitzgerald Rating: Overweight Old Target: $34 New Target: $14 Maintain
22/09/2017 Broker: SunTrust Old Rating: Buy New Rating: Hold Old Target: $25 Downgrade
22/09/2017 Broker: Cowen & Co Old Rating: Outperform New Rating: Market Perform Downgrade
22/09/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Underweight Old Target: $28 Downgrade
08/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain

It closed at $2.05 lastly. It is down 103.18% since January 19, 2017 and is uptrending. It has outperformed by 86.48% the S&P500.

Versartis, Inc. operates as an endocrine-focused biopharmaceutical firm in the United States. The company has market cap of $73.41 million. The firm is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase III clinical trials for the treatment of growth hormone deficiency. It currently has negative earnings. It develops drug candidates that it has licensed from Amunix Operating, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.